Predictive importance of comorbidity in patients with myocardial infarction and different strategy of treatment

The aim of the study was to compare the 1-year results of conservative and invasive tactics of treating myocardial infarction (MI) in patients with different severity of comorbid background.

Material and methods. The presented results are based on registry in City Hospital No. 4 of Sochi. The present analysis included patients with a diagnosis of myocardial infarction (n = 1 176). Upon discharge from the hospital, all patients underwent analysis of the severity of comorbidity using the Charlson Comorbidity Index (CCI). A year later, 791 patients managed to find out the prognosis after discharge from the hospital. 1-year mortality was 12.6 % (n = 100).

Results. The frequency of coronary angiography (CA) and percutaneous coronary intervention (PCI) in patients with CCI = 0 (no or minimal comorbidity, n = 408) was 84.3 % and 63.5 %, with a CCI of 1–2 (moderate comorbidity), n = 438) was 68.0 % and 44.8 %, with CCI ≥ 3 (expressed comorbidity, n = 330) was 50.3 % and 25.8 %, respectively. At the same time, conducting PCI at the hospital observation stage was associated with a decrease mortality during the year after discharge from the hospital from 18.5 % to 5.8 %, p < 0.0001. The greatest positive effect of PCI for optimizing the long-term prognosis of (1 year) was achieved in the group of patients with severe comorbidity (CCI ≥ 3), where the NNT (number needed to treat) was 7. The relative risk of 1-year mortality in patients with severe comorbidity compared to the minimum in the PCI group was 6.75, in the conservative treatment group was 4.63.

Conclusion. The results of this study showed that PCI in MI is more often performed by younger, less comorbid patients with a lower risk on the GRACE scale. At the same time, the 1-year survival of patients with MI was significantly higher after PCI compared to the primary conservative treatment strategy, regardless of the severity of comorbidity, and the greatest improvement in the long-term prognosis of PCI was observed in patients with severe comorbidity, as determined by the CCI ≥ 3.

1. Barnett K, Mercer SW, Norbury M et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study. The Lancet. 2012; 380 (9836): 37–43. DOI: 10.1016/S0140–6736(12)60240–2.

2. Canivell S, Muller O, Gencer B et al. Prognosis of cardiovascular and noncardiovascular multimorbidity after acute coronary syndrome. PLoS ONE. 2018; 13 (4): e0195174. doi.org/10.1371/journal.pone.0195174.

3. Castellon X, Bogdanova V. Chronic Inflammatory Diseases and Endothelial Dysfunction. Aging Dis. 2016; 7 (1): 81–89. DOI: 10.14336/AD.2015.0803.

4. Chen HY, Saczynski1 JS, McManus DD et al. The impact of cardiac and noncardiac comorbidities on the short-term outcomes of patients hospitalized with acute myocardial infarction: a population-based perspective. Clinical Epidemiology. 2013: 5; 439–448.

5. Choi DH, Kang SH, Song H. Mean platelet volume: a potential biomarker of the risk and prognosis of heart disease. Korean J. Intern Med. 2016; 31 (6): 1009–1017.

6. Dégano IR, Subirana I, Fusco D et al. Percutaneous coronary intervention reduces mortality in myocardial infarction patients with comorbidities: Implications for elderly patients with diabetes or kidney disease. International Journal of Cardiology. 2017; 249: 83–89. doi.org/10.1016/j.ijcard.2017.07.054.

7. Fassaa A, Urbanb P, Radovanovic D et al. Impact of comorbidities on clinical presentation, management and outcome of patients with acute coronary syndrome. Cardiovascular Medicine. 2010; 13 (5): 155–161.

8. Ferreira GD, Simo JA, Senaratna C et al. Physiological markers and multimorbidity: A systematic review. Journal of Comorbidity. 2018; 8: 1–10.

9. Forman DE, Maurer MS, Boyd C et al. Multimorbidity in Older Adults With Cardiovascular Disease. J Am Coll Cardiol. 2018; 71 (19): 2149–2161. DOI: 10.1016/j.jacc.2018.03.022.

10. Gudnadotti GS. Beyond Randomized Clinical Trials: Multi–morbidity, Age and Gender Impact on the Treatment of Coronary Artery Disease. Reykjavik, Iceland. 2018; 213 p. ISBN: 978–9935–9365–6–1.

11. Hall M, Dondo TB, Yan AT et al. Multimorbidity and survival for patients with acute myocardial infarction in England and Wales: Latent class analysis of a nationwide population-based cohort. PLoS Med. 2018; 15 (3): e1002501. DOI.org/10.1371/journal.pmed.1002501.

12. Hartley A, Marshall DC, Salciccioli JD et al. Trends in mortality from ischemic heart disease and cerebrovascular disease in Europe: 1980 to 2009. Circulation. 2016; 133 (20): 1916–1926. DOI: 10.1161/circulationaha.115.018931.

13. Hudzik B, Korzonek-Szlacheta I, Szkodziński J et al. Association between multimorbidity and mean platelet volume in diabetic patients with acute myocardial infarction. Acta Diabetol. 2018; 55 (2): 175–183. DOI: 10.1007/s00592–017–1079–6.

14. Ibanez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39 (2): 119–177. DOI: 10.1093/eurheartj/ehx393.

15. Karabag T, Altuntas E, Kalayci B et al. The relationship of Charlson omorbidity index with stent restenosis and extent of coronary artery disease. Interventional Medicine & Applied Science. 2018; 10 (2): 70–75.

16. Malkin CJ, Prakash R, Chew DP. The impact of increased age on outcome from a strategy of early invasive management and revascularisation in patients with acute coronary syndromes: retrospective analysis study from the ACACIA registry. BMJ Open. 2012; 2 (1): e000540.

17. Núñez JE, Núñez E, Fácila L et al. Prognostic Value of Charlson Comorbidity Index at 30 Days and 1 Year After Acute Myocardial Infarction. Rev Esp Cardiol. 2004; 57 (9): 842–849.

18. Radovanovic D, Seifert B, Urban P et al. Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002–2012. Heart. 2014; 100: 288–294. DOI: 10.1136/heartjnl-2013–304588.

19. Tegn N, Abdelnoor M, Aaberge L et al. Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial nfarction or unstable angina pectoris (After Eighty study): an open–label randomised controlled trial. Lancet. 2016; 387 (10023): 1057–1065. DOI: 10.1016/S 0140–6736(15)01166–6.

20. Tisminetzky M, Gurwitz JH, Miozzo R et al. Impact of cardiacand noncardiac-related conditions on adverse outcomes in patients hospitalized with acute myocardial infarction. Journal of Comorbidity. 2019; 9: 1–9.

21. Tran J, Norton R, Conrad N et al. Patterns and temporal trends of comorbidity among adult patients with incident cardiovascular disease in the UK between 2000 and 2014: A population–based cohort study. PLoS Med. 2018; 15 (3): e1002513. doi.org/10.1371/journal.pmed.1002513.

22. Wolff G, Dimitroulis D, Andreotti F et al. Survival Benefits of Invasive Versus Conservative Strategies in Heart Failure in Patients With Reduced Ejection Fraction and Coronary Artery Disease A Meta-Analysis. Circ Heart Fail. 2017; 10: e003255. DOI: 10.1161/circheartfailure.116.003255.

23. Барбараш О. Л., Кашталап В. В. Четвертое универсальное определение инфаркта миокарда. Фокус на инфаркт миокарда 2-го типа. Фундаментальная и клиническая медицина. 2018; 3 (4): 73–82. DOI: 10.23946/2500–0764–2018–3–4–73–82.

24. Барбараш О. Л. Европейская программа Stent for Life: предпосылки, история создания, основные цели и задачи. Комплексные проблемы сердечно-сосудистых заболеваний. 2013; 1: 10–18.

25. Демографический ежегодник России. 2017: Стат. сб. / Росстат. M., 2017. 263 c. ISBN 978–5–89476–447–4.

26. Зыков М. В., Кашталап В. В., Быкова ИС и др. Связь мультиморбидности с риском развития сердечно–сосудистых осложнений у пациентов с острым коронарным синдромом. Кардиологический вестник. 2018; 2: 59–65.

27. Оганов Р. Г., Симаненков В. И., Бакулин И. Г. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019; 18 (1): 5–66. DOI: 10.15829/1728–8800–2019–1–5–66.

28. Оксенойт Г. К., Никитина С. Ю., Агеева Л. И. и др. Здравоохранение в России. Под ред. Г. К. Оксенойт, С. Ю. Никитина, Л. И. Агеева, Г. А. Александрова, Н. М. Зайченко, Г. Н. Кириллова и др. Здравоохранение в России. М.: Росстат; 2017. 170 с.